Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | stella

Back to Advanced Lymphoma trials

Active, not recruiting

Plain-English translation of NCT02465060 on ClinicalTrials.gov ↗ · Source last updated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations

(1411 sites)

United States

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

Thomas Hospital, Fairhope, Alabama

Mobile Infirmary Medical Center, Mobile, Alabama

University of South Alabama Mitchell Cancer Institute, Mobile, Alabama

Anchorage Associates in Radiation Medicine, Anchorage, Alaska

Key details

Phase

Testing effectiveness

Sponsor

National Cancer Institute (NCI)

Enrollment target

~6,452 participants

Started

August 2015

Primary completion

December 2026

Age range

18 Years and older

Last updated on clinicaltrials.gov in June 2026.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov